Literature DB >> 33871804

Comment on "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".

Carlos Antonio Moura1,2,3, Fabiana Santos Rosa4,5, Luiz Henrique Assis4, Carlos Geraldo Moura4,5.   

Abstract

Entities:  

Year:  2021        PMID： 33871804     DOI： 10.1007/s40266-021-00857-3

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


× No keyword cloud information.
  9 in total

1.  Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.

Authors:  Arianna Masciulli; Alberto Ferrari; Alessandra Carobbio; Arianna Ghirardi; Tiziano Barbui
Journal:  Blood Adv       Date:  2020-01-28

Review 2.  Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?

Authors:  Ian C Scott; Samantha L Hider; David L Scott
Journal:  Drug Saf       Date:  2018-07       Impact factor: 5.606

Review 3.  Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.

Authors:  Abril Verden; Mo Dimbil; Robert Kyle; Brian Overstreet; Keith B Hoffman
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

4.  The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.

Authors:  Clodagh Keohane; Donal P McLornan; Katy Sanchez; Christopher Connor; Deepti Radia; Claire N Harrison
Journal:  Haematologica       Date:  2015-06-18       Impact factor: 9.941

5.  Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.

Authors:  Giuseppina Novo; Daniela Di Lisi; Enrico Bronte; Francesca Macaione; Vincenzo Accurso; Giuseppe Badalamenti; Gaetana Rinaldi; Sergio Siragusa; Salvatore Novo; Antonio Russo
Journal:  Oncology       Date:  2020-04-29       Impact factor: 2.935

Review 6.  The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).

Authors:  Fatima Ardito; Michele Giuliani; Donatella Perrone; Giuseppe Troiano; Lorenzo Lo Muzio
Journal:  Int J Mol Med       Date:  2017-06-22       Impact factor: 4.101

7.  Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.

Authors:  Philip J Mease; Apinya Lertratanakul; Jaclyn K Anderson; Kim Papp; Filip Van den Bosch; Shigeyoshi Tsuji; Eva Dokoupilova; Mauro Keiserman; Xin Wang; Sheng Zhong; Reva M McCaskill; Patrick Zueger; Aileen L Pangan; William Tillett
Journal:  Ann Rheum Dis       Date:  2020-12-03       Impact factor: 19.103

Review 8.  Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk.

Authors:  Suraj Rajasimhan; Omer Pamuk; James D Katz
Journal:  Drugs Aging       Date:  2020-08       Impact factor: 3.923

9.  Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.

Authors:  Iain B McInnes; Nicole L Byers; Richard E Higgs; Jonathan Lee; William L Macias; Songqing Na; Robert A Ortmann; Guilherme Rocha; Terence P Rooney; Thomas Wehrman; Xin Zhang; Steven H Zuckerman; Peter C Taylor
Journal:  Arthritis Res Ther       Date:  2019-08-02       Impact factor: 5.156
  9 in total
  1 in total

1.  Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk".

Authors:  Suraj Rajasimhan; Omer Pamuk; James D Katz
Journal:  Drugs Aging       Date:  2021-04-19       Impact factor: 3.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.